
EPISODE 1 META (150–160 CHAR) Drs. Miller and Vue frame platinum-resistant ovarian cancer, define the 6-month threshold, and review the bevacizumab, mirvetuximab, and T-DXd backbone of current care.

EPISODE 1 META (150–160 CHAR) Drs. Miller and Vue frame platinum-resistant ovarian cancer, define the 6-month threshold, and review the bevacizumab, mirvetuximab, and T-DXd backbone of current care.

The ROSELLA trial is particularly exciting, in my opinion.

Having this many therapeutic options for patients in this space is both exciting and a privilege.